Cosmos Health Inc. (NASDAQ:COSM) Sees Significant Growth in Short Interest

Cosmos Health Inc. (NASDAQ:COSM) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,744,953 shares, an increase of 102.5% from the June 15th total of 2,343,632 shares. Currently, 10.3% of the company’s stock are short sold. Based on an average daily volume of 15,984,868 shares, the days-to-cover ratio is presently 0.3 days.

Cosmos Health Stock Down 1.3%

COSM stock traded down $0.00 during mid-day trading on Thursday, reaching $0.28. The company had a trading volume of 2,959,788 shares, compared to its average volume of 4,607,824. The company has a market capitalization of $17.07 million, a price-to-earnings ratio of -0.43 and a beta of 4.83. Cosmos Health has a 52 week low of $0.16 and a 52 week high of $1.32. The stock has a 50 day simple moving average of $0.25 and a two-hundred day simple moving average of $0.35. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.08 and a quick ratio of 0.92.

Cosmos Health (NASDAQ:COSM) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $18.40 million during the quarter, compared to the consensus estimate of $17.93 million. Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%. As a group, equities analysts predict that Cosmos Health will post -0.06 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Grigorios Siokas purchased 701,447 shares of Cosmos Health stock in a transaction dated Wednesday, June 10th. The stock was bought at an average price of $0.23 per share, for a total transaction of $161,332.81. Following the completion of the acquisition, the chief executive officer directly owned 13,263,361 shares of the company’s stock, valued at $3,050,573.03. This represents a 5.58% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Georgios Terzis acquired 168,135 shares of the stock in a transaction dated Tuesday, June 16th. The shares were bought at an average cost of $0.25 per share, with a total value of $42,033.75. Following the transaction, the chief financial officer directly owned 2,235,398 shares of the company’s stock, valued at $558,849.50. This represents a 8.13% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 1,088,029 shares of company stock worth $249,240 in the last quarter. 26.15% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cosmos Health

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd boosted its stake in shares of Cosmos Health by 52.1% during the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after acquiring an additional 34,117 shares during the period. Renaissance Technologies LLC increased its position in Cosmos Health by 16.7% during the 1st quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock worth $124,000 after buying an additional 55,925 shares during the period. Finally, Citadel Advisors LLC raised its position in shares of Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after buying an additional 128,776 shares in the last quarter. Institutional investors and hedge funds own 12.61% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cosmos Health in a research report on Monday, June 15th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.